BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37972575)

  • 21. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.
    del Re E; Babitt JL; Pirani A; Schneyer AL; Lin HY
    J Biol Chem; 2004 May; 279(21):22765-72. PubMed ID: 14996829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.
    Tazat K; Hector-Greene M; Blobe GC; Henis YI
    Mol Biol Cell; 2015 Oct; 26(19):3535-45. PubMed ID: 26269580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.
    Liu S; Nheu T; Luwor R; Nicholson SE; Zhu HJ
    J Biol Chem; 2015 Jul; 290(29):17894-17908. PubMed ID: 26032413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver.
    Liu C; Billadeau DD; Abdelhakim H; Leof E; Kaibuchi K; Bernabeu C; Bloom GS; Yang L; Boardman L; Shah VH; Kang N
    J Clin Invest; 2013 Mar; 123(3):1138-56. PubMed ID: 23454766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
    Lenferink AE; Magoon J; Cantin C; O'Connor-McCourt MD
    Breast Cancer Res; 2004; 6(5):R514-30. PubMed ID: 15318933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin cells according to distinct levels of TbetaRII expression.
    Bandyopadhyay B; Han A; Dai J; Fan J; Li Y; Chen M; Woodley DT; Li W
    J Cell Sci; 2011 Jan; 124(Pt 1):19-24. PubMed ID: 21172820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
    Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
    J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-molecule force spectroscopy study of interaction between transforming growth factor beta1 and its receptor in living cells.
    Yu J; Wang Q; Shi X; Ma X; Yang H; Chen YG; Fang X
    J Phys Chem B; 2007 Dec; 111(48):13619-25. PubMed ID: 17997544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation.
    Yoshimatsu Y; Wakabayashi I; Kimuro S; Takahashi N; Takahashi K; Kobayashi M; Maishi N; Podyma-Inoue KA; Hida K; Miyazono K; Watabe T
    Cancer Sci; 2020 Jul; 111(7):2385-2399. PubMed ID: 32385953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric TβRII-SE/Fc overexpression by a lentiviral vector exerts strong antitumoral activity on colorectal cancer-derived cell lines in vitro and on xenografts.
    Romo A; Rodríguez TM; Yu G; Dewey RA
    Cancer Gene Ther; 2024 Jan; 31(1):174-185. PubMed ID: 37993543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of hypoxia on expression of transforming growth factor-beta1 and its receptors I and II in the amoeboid microglial cells and murine BV-2 cells.
    Li JJ; Lu J; Kaur C; Sivakumar V; Wu CY; Ling EA
    Neuroscience; 2008 Oct; 156(3):662-72. PubMed ID: 18760335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling.
    Kim SK; Barron L; Hinck CS; Petrunak EM; Cano KE; Thangirala A; Iskra B; Brothers M; Vonberg M; Leal B; Richter B; Kodali R; Taylor AB; Du S; Barnes CO; Sulea T; Calero G; Hart PJ; Hart MJ; Demeler B; Hinck AP
    J Biol Chem; 2017 Apr; 292(17):7173-7188. PubMed ID: 28228478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cells.
    Tarakanova VL; Wold WS
    J Virol; 2003 Sep; 77(17):9324-36. PubMed ID: 12915548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors.
    Zhao L; Liu S; Che X; Hou K; Ma Y; Li C; Wen T; Fan Y; Hu X; Liu Y; Qu X
    Int J Mol Med; 2015 Sep; 36(3):645-52. PubMed ID: 26133118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-β signals promote progression of squamous cell carcinoma by inducing epithelial-mesenchymal transition and angiogenesis.
    Ibi H; Takahashi K; Harada H; Watabe T; Podyma-Inoue KA
    Biochem Biophys Res Commun; 2024 Jun; 714():149965. PubMed ID: 38657447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.